key: cord-0696789-9psf7mht
authors: Manaa, Amir; Ziv, Michael; Krausz, Judit; Dodiuk‐Gad, Roni P.
title: A case of symmetrical drug‐related intertriginous and flexural exanthema‐like eruption associated with Pfizer COVID‐19 vaccination
date: 2022-05-12
journal: Dermatol Ther
DOI: 10.1111/dth.15546
sha: feb0597b79c53db74c9ed6ba8671857d88d8e565
doc_id: 696789
cord_uid: 9psf7mht

nan

Owing to an insufficient response to topical and systemic corticosteroids (dosage up to 40 mg prednisone for 2 weeks) and mood changes experienced by the patient due to the high dose of prednisone, we decided to add treatment with 100 mg cyclosporine twice daily (2.5 mg/kg per day) and the patient was tapered off prednisone over the course of 2 weeks until its discontinuation. Treatment with cyclosporine was continued at this dosage for 1 month with good response and reduction of the pronounced inflammatory reaction.

The dosage of cyclosporine was then tapered off over 1.5 months until discontinuation, with maintenance of clinical response. Laboratory examination showed that the leukocyte value had returned to the normal range. It should be noted that no treatment side effects were recorded; the patient was able to return to his daily activities and was very satisfied with the treatment. SDRIFE, previously known as baboon syndrome, is a type IV/delayed hypersensitivity immune response, presenting as symmetrical erythema of the gluteal and intertriginous areas, with the absence of systemic symptoms. It is triggered by exposure to systemic drugs, most commonly beta-lactam antibiotics, but also many other agents. 4 Four cases of SDRIFE-like eruption due to COVID-19 vaccination have been reported to date (Table 1) 

Data. Coronavirus (COVID-19) vaccinations

Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from Northeast Italy

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases

A systematic approach to systemic contact dermatitis and symmetric drug-related intertriginous and flexural exanthema (SDRIFE): a closer look at these conditions and an approach to intertriginous eruptions

Systemic drug-related intertriginous and flexural exanthema like eruption after CoronaVac vaccine

Symmetrical drug-related intertriginous and flexural exanthema like eruption associated with COVID-19 vaccination

Systemic drug-related intertriginous and flexural exanthema induced by the Pfizer-BioNTech COVID-19 vaccine: a report of 2 cases